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Abstract 1 
Introduction 2 
Limited data are available on population-level herd effects of infant 10-valent Pneumococcal 3 
Conjugate Vaccine (PCV10) programmes on pneumonia. We assessed national trends in 4 
pneumococcal and all-cause pneumonia hospitalisations in adults ≥18 years, before and after infant 5 
PCV10 introduction in 2010.  6 
Methods 7 
Monthly hospitalisation rates of ICD-10 coded primary discharge diagnoses compatible with 8 
pneumonia from 2004-05 to 2014-15 were calculated with population denominators from the 9 
Population Register. Trends in pneumonia before and after PCV10 introduction were assessed with 10 
interrupted time-series analysis. Rates during the PCV10 period were estimated from adjusted 11 
negative binomial regression model and compared with those projected as continuation of the pre-12 
PCV10 trend. All-cause hospitalisations were assessed for control purposes.  13 
Results 14 
Before PCV10, the all-cause pneumonia rate in adults >18 years increased annually by 2.4%, followed 15 
by a 4.7% annual decline during the PCV10 period. In 2014-15, the overall all-cause pneumonia 16 
hospitalisation rate was 109.3/100,000 (95% CI: 96.5, 121.9) - 15.4% lower than the expected rate. A 17 
significant 6.7% decline was seen in persons >65 years (131.5/100,000), which translates to 1456 18 
fewer pneumonia hospitalisations annually. In comparison, hospitalisations other than pneumonia 19 
decreased by 3.5% annually throughout the entire study period.  20 
Conclusion 21 
These national data suggest that herd protection from infant PCV10 programme has reversed the 22 
increasing trend and substantially decreased all-cause pneumonia hospitalisations in adults, 23 
particularly the elderly. 24 
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Summary Box 3 
What is the key question? 4 
In a nationwide, population-based study, we assessed whether vaccinating infants with the 10-valent 5 
pneumococcal conjugate vaccine (PCV10) had had an impact on adult pneumonia hospitalisations 6 
through herd protection. 7 
What is the bottom line? 8 
Although there was an increasing trend in rates of pneumonia before PCV10, five years after infant 9 
PCV10 introduction all-cause pneumonia hospitalisations had decreased significantly in all adult age 10 
groups, particularly the elderly.  11 
Why read on? 12 
In high-income countries, the ageing of population and the uncertain cost-effectiveness of preventing 13 
adult pneumococcal disease by direct vaccination highlight the public health significance of the 14 
pneumococcal conjugate vaccine programme's indirect impact in reducing the burden of adult 15 
pneumonia. 16 
 17 
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INTRODUCTION 1 
Lower respiratory infections are the fourth common cause of death globally [1]. Community-acquired 2 
pneumonia (CAP) causes significant clinical and economic burden associated with hospitalisations, 3 
particularly in the elderly [2]. Recent estimates of the proportion of CAP that is attributable to 4 
Streptococcus pneumoniae (pneumococcus) in adults have ranged from 19% to 27%. However, 5 
because sensitive and specific assays are not routinely used in clinical practice – particularly for non-6 
hospitalised cases – these estimates may be conservative [3, 4]. In a recent prospective cohort study 7 
of Finnish adults ≥65 years of age, CAP incidence was estimated to be 1050 cases/100,000 person-8 
years; 17% of cases were due to S. pneumoniae, and 85% required hospitalisation [5]. In the U.S., the 9 
annual incidence of hospitalised CAP in adults ≥85 years of age was estimated to be >1600 10 
cases/100,000 [6].  11 
Pre-licensure clinical trials suggested a 20-40% effectiveness of the 7-valent pneumococcal conjugate 12 
vaccine (PCV7) against radiologically confirmed-pneumonia in children ≤ 5 years of age [7, 8]. In 13 
persons ≥65 years of age, one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) 14 
reduced vaccine-serotype CAP by 45% in the Netherlands, but had little impact on overall pneumonia 15 
[9]. After introduction of PCV7 – and subsequently PCV13 – in routine infant immunization 16 
programmes, several population-based studies reported reductions in all-cause pneumonia 17 
hospitalisations in children [10, 11]. In Finland, PCV10 introduction was recently shown to have 18 
substantially decreased the incidence of pneumonia in both vaccine-eligible and older, unvaccinated 19 
children [12]. Infant PCV vaccination decreases carriage of vaccine-serotype pneumococci and, 20 
consequently, transmission to unvaccinated groups [13]. Few studies, however, have evaluated the 21 
population-level herd effects of infant PCVs on adult pneumonia hospitalisations [14–17]. Given the 22 
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increasing burden of pneumonia hospitalisations associated with ageing of the population, reducing 1 
morbidity and mortality from pneumonia in adults by infant pneumococcal vaccination would yield 2 
major public health benefits [18]. 3 
We conducted a nation-wide register-linkage study to assess the public health impact of infant PCV10 4 
programme introduction on all-cause and pneumococcal pneumonia hospitalisations in adults ≥18 5 
years of age in Finland. 6 
 7 
 8 
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METHODS  1 
Pneumococcal vaccination in Finland  2 
In September 2010, PCV10 was introduced in the Finnish National Vaccination Programme (NVP) 3 
under a 3-dose schedule (at 2, 5, and 12 months of age) without catch-up programme. All children 4 
born after June 2010 were eligible. In the 2012 birth cohort, the uptake of at least one dose of PCV10 5 
was estimated to be 94% [19]. Use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) 6 
and PCV13 in adults at-risk and the elderly is recommended. However, there is no national adult 7 
vaccination program and in 2014 the cumulative coverage of both vaccines in adults was <5% on the 8 
basis of vaccine distribution data. 9 
Study population and data sources 10 
This was a nation-wide, population-based, quasi-experimental study. The national hospital discharge 11 
register includes discharge notifications for inpatient admissions and outpatient visits from all Finnish 12 
hospitals. ICD-10 coded discharge diagnoses and visit dates for pneumonia hospitalisations in all 13 
adults ≥18 years of age from 2004-05 to 2014-15 (epidemiologic years from July to June) were 14 
extracted; population denominators were from the population information system. Data were 15 
analysed in the following age groups: 18-49, 50-64, ≥65 and, ≥18 years of age. The age group ≥65 16 
years was further divided into 65-74, 75-84, and ≥85 years of age. 17 
Pneumonia definitions 18 
All-cause pneumonia hospitalisation was defined as record of a patient hospitalised for at least 19 
overnight with ICD-10 coded pneumonia as the primary discharge diagnosis (J10-J18, and J86; 20 
Supplementary File: Tables 1 and 2). Pneumococcal pneumonia and empyema were defined as 21 
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patients with ICD-codes J13 and J86, respectively, in any discharge diagnosis field, with or without 1 
overnight hospitalisation. Potential multiple pneumonia discharge records for the same patient within 2 
90 days from the date of the index pneumonia diagnosis were combined into one episode. The 3 
hospital discharge dataset included no radiological data. All-cause hospitalisations, defined as records 4 
of patients hospitalised for at least overnight with ICD-10 discharge codes other than J10-J18, and J86 5 
were assessed for comparison. 6 
Statistical analysis 7 
Interrupted time-series analysis was used to compare rates of adult pneumonia before and after 8 
infant PCV10 introduction. The comparison periods for analysis included the pre-PCV10 period 9 
(epidemiologic years from 2004-05 to 2009-10; i.e. 72 monthly data points), and the PCV10 period 10 
(epidemiologic years from 2011-12 to 2014-15; i.e. 48 monthly data points); 2010-11 was considered 11 
a transitional period and excluded from the analysis. 12 
Separate models were fitted for each case definition (all-cause pneumonia, pneumococcal 13 
pneumonia, empyema, and all-cause hospitalisations), age-group, and for the whole adult population. 14 
In all models, the outcome was the monthly number of episodes with the log of the 15 
population/100,000 as offset [20], and the reported measure was monthly incidence rate ratio, which 16 
was exponentiated to estimate the annual incidence rate ratio. The model parameters included the 17 
baseline rate at the beginning of the study and the trend before and after PCV10 introduction. Our 18 
model did not include the change in level as an immediate effect after the intervention because this is 19 
more relevant for studying the direct effect of PCVs on pneumonia hospitalisations in vaccine-eligible 20 
children [11]. In contrast, PCV-attributed herd protection in adults appears to have a “lag period” 21 
before coming into full effect [21] and in the absence of a clear definition of such lag period, setting 22 
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the time point for the change in level a priori would have been largely subjective. All models were 1 
adjusted for sex, and models for the aggregate age-groups were age-adjusted. To account for 2 
seasonal fluctuation in rates, all models included a Fourier seasonality component with the linear 3 
combinations of sine and cosine functions: 4 
log E(Yt) = log(Ct) + β0 + β1Tt + β2XtTt + β3sin[2π/12] + β4cos[2π/12] + β5Gt 5 
Where Yt is the number of pneumonia episodes measured at month t. log(Ct) is the offset equal to the 6 
log of the population Ct divided by 100,000. β0 is baseline rate. Tt is the time since the beginning of the 7 
study until month t, and β1 is the pre-PCV10 slope. XtTt is an interaction term and β2 represents the 8 
post-PCV10 trend. The sine and cosine terms represent the Fourier seasonality component. Gt is a 9 
binary representing sex.  10 
Trends in pneumonia episodes before and after PCV10 were compared by estimating annual 11 
incidence rate ratios (IRR) per 100,000 with the corresponding 95% confidence interval (CI). The IRR of 12 
the trend before-PCV10 is estimated as the change in annual hospitalisation rates from the first year 13 
in the observation period. The IRR of the trend after-PCV10 is estimated as the comparison of the 14 
annual trend in hospitalisation rate following the start of the PCV10 period to the period before. 15 
Percentage annual changes in trend were calculated as (IRR-1) x 100.  16 
To quantify the indirect impact of PCV10, the rate at the end of the study period (i.e. epidemiologic 17 
year 2014-15) was estimated as the nonlinear prediction from the model with the full set of 18 
parameters, and was then compared with the expected rate that would have occurred in the absence 19 
of PCV10 introduction. The expected rates were nonlinearly predicted as continuation of the trend in 20 
the period before PCV10, by holding the model parameter denoting the trend after PCV10 at zero 21 
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[22]. The number of prevented pneumonia admissions per year was estimated by multiplying the 1 
annual absolute rate reduction by the population size in 2014-15. To smoothen the seasonal variation 2 
in the graphical presentation, symmetrical twelve-month moving average filters were applied to 3 
average monthly estimated and expected rates. Incidence rate residual analysis was done, including 4 
tests for autocorrelation and partial autocorrelations. These indicated no significant deviances from 5 
model assumptions. The level of statistically significant, two-tailed p-value was <0.05. Stata/SE version 6 
14 (Stata, College Station, Texas, USA) was used in statistical analyses. The study protocol was 7 
approved by the institutional review board (IRB) in the National Institute for Health and Welfare 8 
(THL), Finland. Permissions to use the register data for research were obtained from the register 9 
controller at THL. 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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RESULTS 1 
Characteristics of pneumonia hospitalisations  2 
During the study period (2004-04 to 2014-15), >21.7 million hospital discharges were recorded in 3 
Finnish adults ≥18 years of age; 263,382 (1.2%) were all-cause pneumonia hospitalisation episodes. 4 
Pneumococcal pneumonia and empyema accounted for 1.8% and 1.1% of pneumonia episodes, 5 
respectively (Table 1). The baseline rate of and number of all-cause pneumonia hospitalisations in 6 
2004-05 were 502.8/100,000 and 20,823, respectively (Table 2). The baseline rates ranged from 7 
167.9/100,000 in persons 18-49 years of age to 4434.3/100,000 in those ≥85 years of age. The overall 8 
baseline rates for pneumococcal pneumonia and empyema were low (9.1 and 4.8/100,000, 9 
respectively). 10 
Trends in pneumonia rates during the pre-PCV10 period  11 
From July 2004 to June 2010, the rates of all-cause pneumonia hospitalisations in adults ≥18 years of 12 
age increased by 2.4% annually (incidence rate-ratio [IRR] 1.024; 95% CI: 1.018, 1.037) (Table 2). 13 
Similarly, rates of both pneumococcal pneumonia and empyema increased annually by 3.7% and 6.2% 14 
(IRRs 1.037 and 1.062, respectively). Age-stratified trend analysis showed increases in rates of all-15 
cause pneumonia hospitalisations during the pre-PCV10 period in all age groups (Table 2).  16 
Trends in pneumonia rates during the PCV10 period 17 
From July 2011 to June 2015, the all-cause pneumonia rates in adults ≥18 years of age decreased 18 
annually by 4.7% (IRR 0.953; 95% CI: 0.942, 0.965) (Table 2). Statistically significant declines were seen 19 
in all age-specific rates except for adults ≥75 years of age; the largest reduction was seen in age 20 
groups 18-49 and 50-64 years (9.2%). The rate of pneumococcal pneumonia decreased annually by 21 
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8.1% (IRR 0.919; 95% CI: 0.876, 0.965); significant annual declines of 14.5% were seen in adults <65 1 
years of age. Reductions in empyema rates were non-significant (Table 2).  2 
Potential outcomes analysis  3 
 4 
In epidemiologic year 2014-15, the estimated annual rate of all-cause pneumonia hospitalisations in 5 
adults ≥18 years of age was 109.3 episodes/100,000 (95% CI: 96.5, 121.9) or 15.4% lower compared 6 
with the expected rate on the basis of pre-PCV10 trends (Table 3, Figure 1a). For pneumococcal 7 
pneumonia, the overall rate reduction in 2014 was estimated to be 3.5 episodes per 100,000 (95% CI: 8 
2.5, 4.4), or 26.5%. By 2014-15, the overall reduction in empyema was 1.5 episodes/100,000 (95% CI: 9 
0.9, 2.1) (Table 3).  10 
In age-stratified analyses, statistically significant reductions in all-cause pneumonia hospitalisations 11 
were seen in all age groups (Table 3, Figure 2). Compared with the expected rate, the estimated 12 
reductions in all-cause pneumonia hospitalisations in age-groups 18-49, 50-64, and ≥65 years were 13 
44.1 (26.9%), 140.6 (28.8%), and 131.5 (6.7%) per 100,000 person-years, respectively. The greatest 14 
absolute reduction was seen in persons ≥85 years (195.9/100,000). During 2014-15, there were a total 15 
of 20,506 pneumonia hospitalisations among the 1,107,240 persons ≥65 years of age; the estimated 16 
rate decrease translates to 1456 fewer pneumonia hospitalisations in this age-group. Likewise, the 17 
estimated rate decreases in age-groups 18-49 (population, 2,180,022) and 50-64 (population, 18 
1,117,998) translate to 961 and 1572 fewer pneumonia hospitalisations in 2014-15, respectively. 19 
Persons <65years of age had an estimated 41% reduction in pneumococcal pneumonia. Similar 20 
percent reduction was seen in persons ≥85 years of age, with the greatest absolute reduction in 21 
pneumococcal pneumonia rates (13.0 episodes/100,000). In persons 75-84 years of age, however, the 22 
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estimated rates were higher than expected by 5.4 episodes/100,000. By the end of the study period, 1 
the overall and age-stratified rates of empyema were significantly lower than expected, except for the 2 
youngest and the oldest age groups (Table 3). 3 
Control condition: trends in all-cause hospitalisations  4 
 Before PCV10 introduction, all-cause hospitalisations (excluding pneumonia) decreased annually by 5 
3.5% (IRR 0.965; 95% CI: 0.953, 0.976). The trend continued during the PCV10 period (Supplementary 6 
File: Figure 1).   7 
 8 
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DISCUSSION 1 
This study provides evidence of herd effects and population-level impact of an infant PCV10 2 
programme on adult pneumonia hospitalisations in a high vaccine uptake setting. The analysis of 3 
trends and potential outcomes showed an increasing pre-vaccine trend in adult pneumonia 4 
hospitalisations, followed by significant declines in overall- and age-stratified rates after PCV10 5 
introduction. By 2014-15, the rate of all-cause pneumonia hospitalisations in adults had declined by 6 
15% or 109 episodes per 100,000 population. Our data highlight both the substantial burden and 7 
opportunities for prevention of pneumonia in the elderly: Reductions in all-cause pneumonia 8 
hospitalisations in persons ≥65 years of age indicated about 1500 fewer annual hospitalisations.  9 
During the period before PCV10, rates of pneumonia admissions in adults ≥18 years of age increased 10 
by 2.4% annually. Greater rate increases were seen in hospitalisations in which the presumptive 11 
aetiology was reported; as the overall rates of pneumococcal pneumonia and empyema increased by 12 
3.7 and 6% annually. Increasing trends in adult pneumonia admissions were seen in England during 13 
1997-2005, in Denmark during 1994-2004, and in the US during 1988-2002 (i.e. mostly before 14 
introduction of infant PCV7 programmes in these countries) [23-25]. The long-term increasing trend in 15 
pneumonia hospitalisations may be associated with ageing of the population and increase in the 16 
prevalence of underlying medical conditions, both recognized risk factors for CAP [26]. The proportion 17 
of elderly hospitalised pneumonia cases who had underlying medical conditions increased in the US 18 
during 1988-2002 [25]. In the UK, however, an increase in pneumonia admissions in the elderly during 19 
1998-2010 was independent of increases in comorbidities, and was postulated to be associated with 20 
changes in service provision and health seeking behavior [27]. From 1996-2009, the number of 21 
pneumonia hospitalisations in Finland increased by 42%, primarily in the elderly; the duration of 22 
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hospital stay, however, decreased [28]. Changes in coding practices may also be associated with 1 
increases in pneumonia hospitalisations, but this is unlikely to have influenced our findings because 2 
we used only the primary discharge diagnosis and included all pneumonia-related ICD-10 codes in the 3 
analysis. We conducted an additional analysis of all episodes in which ICD-10 coded pneumonia was 4 
listed in any position of the discharge diagnoses, with or without hospitalisation. The relative 5 
reductions in pneumonia where similar to the analysis in which the case definition was restricted to 6 
the primary discharge diagnosis, but the absolute reductions were larger (Supplementary Tables 1 7 
and 2).   8 
Our trend analysis showed significant declines in rates of all-cause pneumonia hospitalisations 9 
following PCV10 introduction. In persons ≥65 years of age, the estimated annual decline was 2.4%, 10 
and in those 18-49 and 50-64 years of age it was 9.2%. In younger adults, rates of pneumococcal 11 
pneumonia also decreased. The large burden of all-cause pneumonia hospitalisations in persons ≥85 12 
years of age, however, was associated with the greatest absolute reduction, an estimated 195.9 fewer 13 
episodes per 100,000 than expected – i.e. had the increasing pre-PCV10 trend continued. Population-14 
based prospective surveillance studies have consistently reported that rates of CAP hospitalisations 15 
increase with advancing age [2, 5]. Pneumonia hospitalisations were previously projected to increase 16 
by 49% from 2010 to 2030 in Finland [28]. Percentage reductions in all-cause pneumonia 17 
hospitalisations by 2015, however, were greatest in young adults (26.9% in adults 18-49 years of age), 18 
which might be associated with reduced exposure to PCV10-serotypes in parents of vaccinated 19 
children. Although previous studies evaluating the impact of infant PCV7 programmes on adult 20 
pneumonia hospitalisations have consistently showed declines in pneumococcal pneumonia, the 21 
reported changes in age-specific all-cause pneumonia hospitalisation rates have varied across settings 22 
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[15, 17]. This variation could be associated with several factors or their combination, including 1 
differences in infant vaccination programmes (e.g. uptake, schedule, or catch-up), population 2 
characteristics, coding practices, admission criteria, or analytical methods.  3 
Some limitations should be considered when interpreting the findings. First, the study design was 4 
ecological. Although our study aimed to estimate the indirect effect of infant PCV10, other adult 5 
vaccines, such as influenza, PCV13, and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), 6 
may also decrease the risk of pneumonia hospitalisation. In Finland, influenza vaccination has been 7 
recommended for all persons ≥65 years of age since 2002. During our study period, the annual 8 
vaccine coverage has varied from 38% to 50%. Uptake was highest during the 2009 influenza 9 
pandemic, but actually decreased in subsequent years, i.e. during PCV10 period. In 2014, the 10 
cumulative coverage of PPSV23 and PCV13 in adults was <5% based on vaccine distribution data. This 11 
low coverage would not be expected to have a population-level impact on overall pneumonia 12 
incidence.  13 
Second, all-cause pneumonia is a non-specific outcome and trends in other respiratory pathogens 14 
may influence its occurrence. In 2010-11, an increase in all-cause pneumonia was observed. Although 15 
this coincided with an epidemic of Mycoplasma pneumoniae infections in Finland, it is unlikely to have 16 
influenced our findings as most cases were in younger age groups (5-19 years of age) and the period 17 
(late-2010 to mid-2011) was excluded from our analysis [29]. In our study, some 95% of episodes 18 
were recorded as pneumonia due to unspecified cause, indicating the lack of sensitive and specific 19 
etiological diagnosis for pneumonia in a routine hospital care [3, 4]. To capture all episodes of 20 
pneumococcal pneumonia and empyema, we used broader case definition (with or without overnight 21 
hospitalisations) and also included non-primary discharge diagnoses. Nevertheless, these outcomes 22 
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accounted for <2% of pneumonia episodes in our study. In previous reports, laboratory-confirmed 1 
pneumococcal pneumonia accounted for a small fraction of all-cause pneumonia hospitalisations [15–2 
17]. In addition, our sensitivity analysis showed no significant changes in pneumonia hospitalisations 3 
due to specified pathogens other than S. pneumoniae (data not shown). Our case definition also 4 
included healthcare-associated pneumonia, which is difficult to distinguish from community-acquired 5 
pneumonia in hospital discharge records and is mainly caused by bacteria other than S. pneumoniae.   6 
Third, administrative data are subject to misclassification, secular changes in coding and clinical 7 
practices, as well as criteria for admission [30]. However, an Australian validation study estimated 8 
98% sensitivity, 97% specificity, 96% positive predictive value, and 98% negative predictive value for 9 
ICD-10 coded pneumonia hospitalisations [31]. In the U.S., comparison of IPD rates reported by active 10 
surveillance with those estimated using ICD-coded data showed similar temporal trends [10]. Changes 11 
in admission criteria might be associated with the observed changes in pneumonia hospitalisation 12 
rates, particularly if there was a shift to management of less severe cases in outpatient settings [32]. 13 
The Finnish guidelines for the management of CAP published in 2008 introduced criteria for 14 
identifying low risk patients who could be managed on outpatient basis [33]. We therefore conducted 15 
a sensitivity analysis which showed that pneumonia hospitalisations continued to increase after the 16 
guidelines were published, and began to decrease only during the PCV10 period (Supplementary File: 17 
Figure 2). However, trends in outpatient visits for CAP could not be examined, as the outpatient 18 
register was established only after PCV10 introduction. The results of an additional analysis, which 19 
also included outpatient and emergency room pneumonia episodes, were similar to the analysis 20 
restricted to hospitalised episodes (Supplementary Tables 1 and 2). It is possible that the decreasing 21 
trend in hospitalisations other than pneumonia might be associated with a shift towards outpatient 22 
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management of various conditions, but this is unlikely to have influenced the observed trends in all-1 
cause pneumonia hospitalisations.  2 
Last, increases in chronic medical conditions which increase the risk of pneumococcal pneumonia also 3 
contribute to the disease burden. We could not assess the potential effect of underlying conditions in 4 
this study due to the complexity of obtaining comprehensive data on these conditions. Assessing 5 
whether indirect vaccine effects against pneumonia are different in persons with and without high 6 
risk conditions will help better defining the characteristics of herd protection in adults. 7 
The strengths of this study included the use of comprehensive, nation-wide, population-based 8 
register data with a case definition for pneumonia hospitalisation with increased specificity of the 9 
main outcome, hospital-treated primary pneumonia. Although our dataset did not include radiological 10 
data, it is likely that our case definition captured most radiologically confirmed episodes as patients 11 
were hospitalised at least overnight and pneumonia was the primary discharge diagnosis. Our data 12 
enabled using interrupted time-series analysis with sufficient data points before and after infant 13 
PCV10 to estimate the herd effect on adult pneumonia hospitalisations. This analysis method had 14 
advantages over the two-point, before-after design because it incorporated multiple time points and 15 
enabled accounting for seasonal variation, and importantly, the pre-vaccine secular increase in 16 
pneumonia hospitalisations in Finland [28]. Last, our analysis showed the trends in all-cause 17 
hospitalisations or potential shifts in outpatient management of CAP were unlikely to explain the 18 
trends in pneumonia hospitalisations. 19 
In conclusion, these national data suggest that herd protection from infant PCV10 has reversed the 20 
increasing trend and substantially decreased all-cause pneumonia hospitalisations in adults, 21 
Page 19 of 31 
 
particularly in the elderly. This finding is significant as the number of persons ≥65 years of age in 1 
Finland is projected to increase by 17% from 2014 to 2020, likely increasing the burden of CAP 2 
hospitalisations even further [34]. The findings also have major implications for economic analyses 3 
comparing strategies for prevention of pneumococcal diseases in adults. 4 
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monthly hospitalisation rate. Estimated rate is the average hospitalisation rate estimated from the 
adjusted negative binomial regression model with the full set of parameters (i.e. time since the 
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independent variable. 12-month moving average filter was applied to both estimated and expected 
rates. 
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